From the Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Cancer J. 2020 Nov/Dec;26(6):548-554. doi: 10.1097/PPO.0000000000000485.
Patients with locally advanced non-small cell lung cancer (NSCLC), a heterogenous group encompassing stage IIIA-IIIC disease, often have surgically unresectable cancer and are managed with concurrent chemoradiation. Since the establishment of platinum-based chemoradiation as standard of care for unresectable locally advanced NSCLC, various strategies including escalating radiation dose, targeted therapies, antiangiogenic agents, and induction or consolidation chemotherapy have failed to show improvement in outcomes. However, recently, use of consolidation immunotherapy with durvalumab following concurrent chemoradiation therapy has been associated with improvement in survival and has led to a paradigm shift. In this review, we will summarize results from trials of immunotherapy in locally advanced NSCLC and comment on ongoing trials and potential future investigations.
局部晚期非小细胞肺癌（NSCLC）患者为一组异质性群体，包括 IIIA 期至 IIIIC 期疾病，这些患者的肿瘤通常无法通过手术切除，且接受同步放化疗治疗。自从将基于铂类的放化疗确立为不可切除的局部晚期 NSCLC 的标准治疗方法以来，各种策略，包括增加放疗剂量、靶向治疗、抗血管生成药物以及诱导或巩固化疗，均未能改善患者的预后。然而，最近，在同步放化疗后使用度伐利尤单抗进行巩固免疫治疗与生存率的提高相关，并引发了治疗模式的转变。在本综述中，我们将总结局部晚期 NSCLC 免疫治疗试验的结果，并对正在进行的试验和潜在的未来研究进行评论。
